Forendo Pharma is a clinical stage drug discovery and development company focusing on novel treatments in women’s health.
The core competence of the company is in modulating tissue specific hormone mechanisms, including leading experience in inhibitors of the HSD17B ((17-beta-hydroxysteroid dehydregonase) enzyme family. Forendo’s pipeline includes HSD17B1 inhibitor (phase I) for the treatment of endometriosis; HSD17B5 inhibitor (discovery) for the treatment of polycystic ovary syndrome (PCOS) and Fispemifene (phase 2), a novel SERM for the treatment of male urological conditions. Forendo’s portfolio also includes a research and collaboration program together with Novartis, aiming at the identification of novel drugs for the treatment of chronic liver diseases.
For more information, please contact: